cancerresearch

Cancer Research

5 Months ago

Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML: Findings suggest AML treatments may be tailored to individual molecular profiles

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial.

  • 0 Likes

  • 0 Comments

See posts by others with similar interest